Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Non-Current Debt (2017 - 2021)

Insight Molecular Diagnostics' Non-Current Debt history spans 3 years, with the latest figure at $178000.0 for Q3 2021.

  • On a quarterly basis, Non-Current Debt fell 91.38% to $178000.0 in Q3 2021 year-over-year; TTM through Sep 2021 was $178000.0, a 91.38% decrease, with the full-year FY2020 number at $1.5 million, down 20.84% from a year prior.
  • Non-Current Debt hit $178000.0 in Q3 2021 for Insight Molecular Diagnostics, down from $541000.0 in the prior quarter.
  • Over the last five years, Non-Current Debt for IMDX hit a ceiling of $2.6 million in Q2 2020 and a floor of $178000.0 in Q3 2021.
  • Historically, Non-Current Debt has averaged $1.4 million across 3 years, with a median of $1.5 million in 2020.
  • Biggest five-year swings in Non-Current Debt: dropped 20.84% in 2020 and later plummeted 91.38% in 2021.
  • Tracing IMDX's Non-Current Debt over 3 years: stood at $1.9 million in 2019, then dropped by 20.84% to $1.5 million in 2020, then plummeted by 88.2% to $178000.0 in 2021.
  • Business Quant data shows Non-Current Debt for IMDX at $178000.0 in Q3 2021, $541000.0 in Q2 2021, and $951000.0 in Q1 2021.